This startup offers a genomic diagnostics platform that utilizes DNA sequencing technology to detect genetic disorders and predispositions. By providing accurate genetic data, it enables healthcare providers to tailor patient care based on individual genetic profiles.
Funding
$554K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional diagnostic methods often require invasive procedures and laboratory analysis, leading to delays in obtaining critical health information. This can hinder timely intervention and proactive health management.
Solution
ArcanaBio is developing a label-free biophotonics platform that enables saliva-based diagnostics for everyday health monitoring. This technology aims to provide real-time access to critical biomarkers, facilitating disease prevention and long-term health management. The platform utilizes ultra-rapid liquid biopsy technology to transform diagnostics and enhance health outcomes through non-invasive methods. By enabling frequent and convenient monitoring, ArcanaBio seeks to empower individuals and healthcare providers with timely insights into health status.
Target Audience
The primary target audience includes individuals seeking proactive health management and healthcare providers aiming to improve diagnostic speed and accessibility.
Features
- Label-free biophotonics platform for saliva-based diagnostics.
- Real-time monitoring of critical biomarkers.
- Ultra-rapid liquid biopsy technology.
- Non-invasive health monitoring.